Evidence map›Paper›PMID 27979319›Full record

ArticleGynecologic oncology2017

Three versus six cycles of adjuvant platinum-based chemotherapy in early stage clear cell ovarian carcinoma - A multi-institutional cohort.

Emily N Prendergast, Marie Holzapfel, Jennifer J Mueller, Mario M Leitao, Camille C Gunderson, Kathleen N Moore, Britt K Erickson, Charles A Leath, Elena S Diaz Moore, Joshua G Cohen and 1 more

Open access · greenAbstract readComparative StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Gynecologic oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
3.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 40 citations in OpenAlex.

  1. An economic analysis of Chemo MouthpieceJournal of comparative effectiveness research · 2026
    Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Observational
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Emily N PrendergastCedars-Sinai Medical Center, Los Angeles, CA, USA.
Marie HolzapfelCedars-Sinai Medical Center, Los Angeles, CA, USA.
Jennifer J MuellerMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Mario M LeitaoMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Camille C GundersonStephenson Oklahoma Cancer Center at the University of Oklahoma, Oklahoma City, OK, USA.
Kathleen N MooreStephenson Oklahoma Cancer Center at the University of Oklahoma, Oklahoma City, OK, USA.
Britt K EricksonUniversity of Alabama at Birmingham, AL, USA.
Charles A LeathUniversity of Alabama at Birmingham, AL, USA.
Elena S Diaz MooreCedars-Sinai Medical Center, Los Angeles, CA, USA.
Joshua G CohenUniversity of California Los Angeles, Los Angeles, CA, USA.
Christine S WalshCedars-Sinai Medical Center, Los Angeles, CA, USA. Electronic address: walshc@cshs.org.
Cedars-Sinai Medical Center · USMemorial Sloan Kettering Cancer Center · USOklahoma State University Oklahoma City · USUniversity of Alabama at Birmingham · USUniversity of California, Los Angeles · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Women's CancerP30CA077598 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Douglas Yee · 1998 to 2026
$100.4M
NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA077598
6 · The paper itself

Abstract

objectivesTo determine if 6 versus 3cycles of adjuvant platinum-based chemotherapy with or without taxane impacts survival in early stage ovarian clear cell carcinoma (OCCC).

methodsWe retrospectively identified all cases of stage I and II OCCC treated at 5 institutions from January 1994 through December 2011. Patients were divided into 2 groups: those who received 3 versus 6cycles of adjuvant chemotherapy. Our cohort consisted of 210 patients with stage IA-II disease, 116 of whom underwent full surgical staging. Cox proportional hazards regression and Kaplan-Meier analyses were performed to evaluate progression-free (PFS) and overall survival (OS) between groups.

resultsAmong 210 eligible patients, the median age was 53years (range 30-88). The majority of patients were Caucasian (83.8%). All patients received adjuvant chemotherapy with 90% receiving carboplatin and paclitaxel. Thirty-eight (18.1%) patients received 3cycles, and 172 (81.9%) patients received 6cycles of adjuvant treatment. Recurrence rate was comparable between groups (18.4% vs. 27.3% for 3 vs. 6cycles, p=0.4). There was no impact of 3 versus 6cycles of chemotherapy on PFS (hazard ratio [HR] 1.4; 95% confidence interval [CI] 0.63-3.12, p=0.4) or OS (HR 1.65; 95% CI 0.59-4.65, p=0.3) on univariate analysis. There was no benefit to more chemotherapy in stratified analysis by stage nor on multivariate analysis adjusting for the impact of stage. Subgroup analysis of surgically staged patients also showed no difference in survival between 3 versus 6cycles of chemotherapy.

conclusionsThree cycles of platinum with or without taxane adjuvant chemotherapy were comparable to 6cycles with respect to recurrence and survival in patients diagnosed with early stage ovarian clear cell carcinoma in this retrospective multi-institutional cohort. CONDENSATION: Three cycles of platinum with or without taxane adjuvant chemotherapy are comparable to 6 cycles with respect to recurrence and survival in patients diagnosed with early stage ovarian clear cell carcinoma in this retrospective multi-institutional cohort.

Indexed as

Adenocarcinoma, Clear CellAdultAgedAged, 80 and overChemotherapy, AdjuvantFemaleHumansMiddle AgedNeoplasm StagingOvarian NeoplasmsPlatinumRetrospective StudiesPlatinumChemotherapyClear cellEarly stageOvarian cancerSurvival

Identifiers

PMID27979319
PMCPMC5530591
OpenAlexW2567564159

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.